News
Positive results for AstraZeneca’s asthma therapy
PT027 is a novel, fixed-dose combination of albuterol and budesonide. AstraZeneca’s drug, at two different strengths of budesonide, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate- to severe asthma.